Scholars Central

Conference abstractPublished 2018

T-cell therapeutic vaccine for autoimmune components of viral infections

Authors: Henri ATLAN

Associate Researcher at Ames Research Center of NASA, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In some autoimmune diseases T-cell populations have been identified as responding to self-antigens and acting as effectors in the pathological autoimmunity. In the procedure of T-cell vaccination (TCV), such cells are cultivated, expanded and reinjected after fixation into the patient, as a vaccine, in order to induce an immune response against tem and protect the organism from their pathological activity. Extensive animal experimentation has shown that TCV was effective in treating various models of autoimmune diseases. Clinical trials have produced positive results on Multiple Sclerosis, rheumatoid arthritis and lupus. Viral infections can trigger autoimmune pathological activity, which develops later into an autonomous way in addition to the direct effects of the virus. That is the case of HIV infection, as experimental evidence has shown. Results of TCV against the autoimmune component of the physiopathology of HIV infection will be presented.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Oncology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Oncology
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Henri ATLAN”